Pooling of clodronate urinary excretion data: A new pharmacokinetic method to study drugs with highly variable gastrointestinal absorption

被引:14
作者
CastrenKortekangas, P [1 ]
Loyttyniemi, E [1 ]
LiukkoSipi, S [1 ]
Juhakoski, A [1 ]
Smal, J [1 ]
Laitinen, K [1 ]
机构
[1] CLIN RES,FIN-00101 HELSINKI,FINLAND
关键词
BONE-DISEASE; BIOEQUIVALENCE;
D O I
10.1359/jbmr.1997.12.1.66
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gastrointestinal absorption of bisphosphonates is highly variable from individual to individual (between-subject variation) and from day to day (within-subject variation), a fact that creates problems both in research and in clinical use of these drugs, We conducted a randomized, two-period cross-over pharmacokinetic (phase I) study to assess the relative bioavailability of two different clodronate preparations: an 800 mg tablet and a 400 mg capsule, Urinary excretion of clodronate correlates with gastrointestinal absorption, To minimize the confounding effect of the high variability of gastrointestinal absorption, we chose as the primary parameter the cumulative amount of clodronate excreted into urine (A(e0-t)) during 9 days (7 days of treatment, 2 days of follow-up), The 90% confidence interval calculated for the population medians of A(e0-t) was 0.83-1.09, well within the 90% confidence interval stipulated for bioequivalence for the area under the curve values (0.80-1.25), This new procedure for pooling urinary excretion data offered a clear advantage over previous methods, and thus could presumably be used to study other drugs as well that are not metabolized and may show highly variable gastrointestinal absorption.
引用
收藏
页码:66 / 71
页数:6
相关论文
共 12 条
[1]  
CASTRENKORTEKAN.P, 1994, STEADY STATE BIOAVAI
[2]   CLODRONATE KINETICS AND DYNAMICS [J].
CONRAD, KA ;
LEE, SM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (01) :114-120
[3]  
EDWARDS OM, 1969, LANCET, V2, P1165
[4]   BISPHOSPHONATES - PHARMACOLOGY AND USE IN THE TREATMENT OF TUMOR-INDUCED HYPERCALCEMIC AND METASTATIC BONE-DISEASE [J].
FLEISCH, H .
DRUGS, 1991, 42 (06) :919-944
[5]  
HAUSCHKE D, 1990, INT J CLIN PHARM TH, V28, P72
[6]  
Jones B., 1989, DESIGN ANAL CROSS OV, P16
[7]  
PENTIKAINEN PJ, 1989, INT J CLIN PHARM TH, V27, P222
[8]   CLODRONATE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY IN RESORPTIVE BONE-DISEASE [J].
PLOSKER, GL ;
GOA, KL .
DRUGS, 1994, 47 (06) :945-982
[9]  
SAHA H, 1994, J BONE MINER RES, V9, P1953
[10]   CONTROVERSIES IN BIOEQUIVALENCE STUDIES [J].
STEINIJANS, VW ;
HAUSCHKE, D ;
JONKMAN, JHG .
CLINICAL PHARMACOKINETICS, 1992, 22 (04) :247-253